Health professionals
EURACAN is a patient-centred European network working to support patients with rare adult solid cancers and their conditions, which require highly specialised care and concentrated knowledge. This results in better chances for patients to receive an accurate diagnosis and advice on the best treatment for their specific disease.
.jpeg)
European Multidisciplinary Tumour Boards (MTBs)
Rare adult solid cancers require expert discussions to ensure accurate diagnosis and effective treatment. To facilitate this exchange, EURACAN regularly sets up multidisciplinary Tumour Boards across the 10 rare solid cancer groups. Health professionals can ask for a second opinion on specific cases to EURACAN experts, through a dedicated platform: the Clinical Patient Management System (CPMS).
The Clinical Patient Management System (CPMS) is a secure platform provided by the European Commission. It allows health professionals, across the UE and recently also from Ukraine to get expert opinions or difficult on rare medical cases during MTBs.
Education and training
The ERN-EURACAN offers different educational opportunities for healthcare professionals willing to specialise in rare cancers. From online courses to exchange programmes, discover our activities.
How to refer your patient
to a EURACAN centre
Primary care physician or oncologist
Refer to a EURACAN expert centre
As a primary care physician or oncologist, you can contact a EURACAN expert centre to organise an appointment or to set up a teleconsultation.
Request second opinion via the CPMS, the European e-tool for sharing patient data
Health professionals can get advice from EURACAN experts about a rare cancer treatment through a free online e-tool. Accessible via both web and mobile applications, the CPMS enables doctors to easily share and discuss intricate cases.
Find out more about rare adult solid cancers
Rare cancer of the connective tissues (sarcoma)
Sarcoma can arise anywhere in the human body, limbs and limb-girdles being the most common primary sites, but all other sites can potentially be affected, including viscera.
Rare cancer of the female genital organs and placenta
These tumours can be divided into three groups: gestational trophoblastic disease (GTD), rare ovarian tumours and all other rare gynaecological cancers arising in the uterus, cervix, vagina and vulva.
Rare cancer of the male genital organs and of the urinary tract
Testicular cancers are rare but they are the most common solid malignancy in men aged between 20 and 40.
Rare cancer of the neuroendocrine system
Neuroendocrine tumours can arise from any organ of the body but most commonly the small bowel, pancreas and lung.
Rare cancer of digestive tract
Rare digestive tract cancers gather a heterogeneous group of malignancies which include primary peritoneal malignancies, biliary tract cancer and anal cancers.
Rare endocrine cancer
Rare thyroid cancers are mainly classified as differentiated thyroid cancer (DTC), anaplastic thyroid cancer (ATC) and medullary thyroid cancer (MTC).
Rare head and neck cancer
Rare head and neck cancers include tumors originating from four different subsites: nasopharyngeal cancer, nasal and paranasal sinus cancers, salivary gland cancers and middle ear epithelial cancers.
Rare thoracic cancer
Rare thoracic tumors correspond to more than 100 different histological, clinical, radiological, and prognostic entities.
Rare skin cancer and uveal melanoma
Rare skin cancers consist of skin sarcomas, Kaposi sarcoma, Merkel cell carcinomas and adnexal tumours.
Rare cancer of the brain and of the spinal cord
Primary brain tumours are often diffuse glial tumours including astrocytomas and oligodendrogliomas from grades II to IV. Other types of rare brain tumours can be merged into a number of clinically relevant groups.